Biguanide
- Generic Name
- Biguanide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C2H7N5
- CAS Number
- 56-03-1
- Unique Ingredient Identifier
- FB4Q52I9K2
- Background
Biguanide has been investigated for the treatment of Diabetes Mellitus.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 294
- Registration Number
- NCT01940965
- Locations
- 🇯🇵
Investigational Site Number 392328, Chiyoda-Ku, Japan
🇯🇵Investigational Site Number 392335, Adachi-Ku, Japan
🇯🇵Investigational Site Number 392310, Chuoh-Ku, Japan
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 374
- Registration Number
- NCT01777282
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 462
- Registration Number
- NCT01301833
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath